Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape. Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 73, 71, 4, 65, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 6, 9 and 1 molecules, respectively. Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology). - The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 8 Kidney Cancer (Renal Cell Cancer) Overview 9 Therapeutics Development 10 Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies 12 Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes 23 Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance 25 Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies 29 Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes 49 Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 51 Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 201 Drug Profiles 235 Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1040 Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1064 Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1069 Appendix 1083
List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016 39 Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2016 40 Number of Products under Development by Companies, H2 2016 41 Number of Products under Development by Companies, H2 2016 (Contd..1) 42 Number of Products under Development by Companies, H2 2016 (Contd..2) 43 Number of Products under Development by Companies, H2 2016 (Contd..3) 44 Number of Products under Development by Companies, H2 2016 (Contd..4) 45 Number of Products under Development by Companies, H2 2016 (Contd..5) 46 Number of Products under Development by Companies, H2 2016 (Contd..6) 47 Number of Products under Development by Companies, H2 2016 (Contd..7) 48 Number of Products under Development by Companies, H2 2016 (Contd..8) 49 Number of Products under Development by Companies, H2 2016 (Contd..9) 50 Number of Products under Development by Companies, H2 2016 (Contd..10) 51 Number of Products under Investigation by Universities/Institutes, H2 2016 53 Comparative Analysis by Late Stage Development, H2 2016 54 Comparative Analysis by Clinical Stage Development, H2 2016 55 Comparative Analysis by Early Stage Development, H2 2016 56 Comparative Analysis by Unknown Stage Development, H2 2016 57 Products under Development by Companies, H2 2016 58 Products under Development by Companies, H2 2016 (Contd..1) 59 Products under Development by Companies, H2 2016 (Contd..2) 60 Products under Development by Companies, H2 2016 (Contd..3) 61 Products under Development by Companies, H2 2016 (Contd..4) 62 Products under Development by Companies, H2 2016 (Contd..5) 63 Products under Development by Companies, H2 2016 (Contd..6) 64 Products under Development by Companies, H2 2016 (Contd..7) 65 Products under Development by Companies, H2 2016 (Contd..8) 66 Products under Development by Companies, H2 2016 (Contd..9) 67 Products under Development by Companies, H2 2016 (Contd..10) 68 Products under Development by Companies, H2 2016 (Contd..11) 69 Products under Development by Companies, H2 2016 (Contd..12) 70 Products under Development by Companies, H2 2016 (Contd..13) 71 Products under Development by Companies, H2 2016 (Contd..14) 72 Products under Development by Companies, H2 2016 (Contd..15) 73 Products under Development by Companies, H2 2016 (Contd..16) 74 Products under Development by Companies, H2 2016 (Contd..17) 75 Products under Development by Companies, H2 2016 (Contd..18) 76 Products under Development by Companies, H2 2016 (Contd..19) 77 Products under Investigation by Universities/Institutes, H2 2016 78 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 79 Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H2 2016 80 Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H2 2016 81 Kidney Cancer (Renal Cell Cancer) - Pipeline by Acceleron Pharma Inc, H2 2016 82 Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 83 Kidney Cancer (Renal Cell Cancer) - Pipeline by Aduro BioTech Inc, H2 2016 84 Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics, H2 2016 85 Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H2 2016 86 Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H2 2016 87 Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc, H2 2016 88 Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corp, H2 2016 89 Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx Inc, H2 2016 90 Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc, H2 2016 91 Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 92 Kidney Cancer (Renal Cell Cancer) - Pipeline by Apac Biotech Pvt Ltd, H2 2016 93 Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H2 2016 94 Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H2 2016 95 Kidney Cancer (Renal Cell Cancer) - Pipeline by Aphios Corp, H2 2016 96 Kidney Cancer (Renal Cell Cancer) - Pipeline by Aptevo Therapeutics Inc, H2 2016 97 Kidney Cancer (Renal Cell Cancer) - Pipeline by Aravive Biologics Inc, H2 2016 98 Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H2 2016 99 Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics Inc, H2 2016 100 Kidney Cancer (Renal Cell Cancer) - Pipeline by ARMO Biosciences Inc, H2 2016 101 Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule Inc, H2 2016 102 Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 103 Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc, H2 2016 104 Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H2 2016 105 Kidney Cancer (Renal Cell Cancer) - Pipeline by ATLAB Pharma SAS, H2 2016 106 Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H2 2016 107 Kidney Cancer (Renal Cell Cancer) - Pipeline by BeiGene Ltd, H2 2016 108 Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H2 2016 109 Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 110 Kidney Cancer (Renal Cell Cancer) - Pipeline by Biocad, H2 2016 111 Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Ltd, H2 2016 112 Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H2 2016 113 Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 114 Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical Inc, H2 2016 115 Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H2 2016 116 Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences Inc, H2 2016 117 Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc, H2 2016 118 Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corp, H2 2016 119 Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellceutix Corp, H2 2016 120 Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics Inc, H2 2016 121 Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 122 Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 123 Kidney Cancer (Renal Cell Cancer) - Pipeline by Cleave Biosciences Inc, H2 2016 124 Kidney Cancer (Renal Cell Cancer) - Pipeline by COARE Biotechnology Inc, H2 2016 125 Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences Inc, H2 2016 126 Kidney Cancer (Renal Cell Cancer) - Pipeline by Corcept Therapeutics Inc, H2 2016 127 Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 128 Kidney Cancer (Renal Cell Cancer) - Pipeline by Cytune Pharma SAS, H2 2016 129 Kidney Cancer (Renal Cell Cancer) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 130 Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 131 Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H2 2016 132 Kidney Cancer (Renal Cell Cancer) - Pipeline by EirGenix Inc, H2 2016 133 Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co Ltd, H2 2016 134 Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2016 135 Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 136 Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis Inc, H2 2016 137 Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 138 Kidney Cancer (Renal Cell Cancer) - Pipeline by Five Prime Therapeutics Inc, H2 2016 139 Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co Ltd, H2 2016 140 Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co Ltd, H2 2016 141 Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H2 2016 142 Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H2 2016 143 Kidney Cancer (Renal Cell Cancer) - Pipeline by HEC Pharm Co Ltd, H2 2016 144 Kidney Cancer (Renal Cell Cancer) - Pipeline by Hemispherx Biopharma Inc, H2 2016 145 Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H2 2016 146 Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison MediPharma Ltd, H2 2016 147 Kidney Cancer (Renal Cell Cancer) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 148 Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp, H2 2016 149 Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H2 2016 150 Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier Inc, H2 2016 151 Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen Inc, H2 2016 152 Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics Inc, H2 2016 153 Kidney Cancer (Renal Cell Cancer) - Pipeline by Incuron LLC, H2 2016 154 Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corp, H2 2016 155 Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 156 Kidney Cancer (Renal Cell Cancer) - Pipeline by Inspyr Therapeutics Inc, H2 2016 157 Kidney Cancer (Renal Cell Cancer) - Pipeline by Intech Biopharm Ltd, H2 2016 158 Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H2 2016 159 Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd, H2 2016 160 Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 161 Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed Inc, H2 2016 162 Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co Ltd, H2 2016 163 Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 164 Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H2 2016 165 Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H2 2016 166 Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics Inc, H2 2016 167 Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H2 2016 168 Kidney Cancer (Renal Cell Cancer) - Pipeline by MediaPharma srl, H2 2016 169 Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune LLC, H2 2016 170 Kidney Cancer (Renal Cell Cancer) - Pipeline by Medivation Inc, H2 2016 171 Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co Inc, H2 2016 172 Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H2 2016 173 Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 174 Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc, H2 2016 175 Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H2 2016 176 Kidney Cancer (Renal Cell Cancer) - Pipeline by Moleculin Biotech Inc, H2 2016 177 Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H2 2016 178 Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc, H2 2016 179 Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 180 Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H2 2016 181 Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corp, H2 2016 182 Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H2 2016 183 Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics Inc, H2 2016 184 Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corp, H2 2016 185 Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc, H2 2016 186 Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics Inc, H2 2016 187 Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc, H2 2016 188 Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H2 2016 189 Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoTherapy Science Inc, H2 2016 190 Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 191 Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics Inc, H2 2016 192 Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc, H2 2016 193 Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharma Mar SA, H2 2016 194 Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmacyclics Inc, H2 2016 195 Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co Ltd, H2 2016 196 Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences Inc, H2 2016 197 Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd, H2 2016 198 Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Ltd, H2 2016 199 Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio SL, H2 2016 200 Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 201 Kidney Cancer (Renal Cell Cancer) - Pipeline by Richter Gedeon Nyrt, H2 2016 202 Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H2 2016 203 Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita SA, H2 2016 204 Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics Inc, H2 2016 205 Kidney Cancer (Renal Cell Cancer) - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 206 Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H2 2016 207 Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics Inc, H2 2016 208 Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 209 Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 210 Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H2 2016 211 Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company Ltd, H2 2016 212 Kidney Cancer (Renal Cell Cancer) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 213 Kidney Cancer (Renal Cell Cancer) - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 214 Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H2 2016 215 Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Ltd, H2 2016 216 Kidney Cancer (Renal Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 217 Kidney Cancer (Renal Cell Cancer) - Pipeline by Theravectys SA, H2 2016 218 Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc, H2 2016 219 Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 220 Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical Inc, H2 2016 221 Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex Inc, H2 2016 222 Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals Ltd, H2 2016 223 Kidney Cancer (Renal Cell Cancer) - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 224 Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd, H2 2016 225 Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc, H2 2016 226 Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H2 2016 227 Kidney Cancer (Renal Cell Cancer) - Pipeline by Vyriad Inc, H2 2016 228 Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals Inc, H2 2016 229 Assessment by Monotherapy Products, H2 2016 230 Assessment by Combination Products, H2 2016 231 Number of Products by Stage and Target, H2 2016 233 Number of Products by Stage and Mechanism of Action, H2 2016 247 Number of Products by Stage and Route of Administration, H2 2016 262 Number of Products by Stage and Molecule Type, H2 2016 264 Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H2 2016 1070 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..1), H2 2016 1071 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..2), H2 2016 1072 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..3), H2 2016 1073 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..4), H2 2016 1074 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..5), H2 2016 1075 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..6), H2 2016 1076 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..7), H2 2016 1077 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..8), H2 2016 1078 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..9), H2 2016 1079 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..10), H2 2016 1080 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..11), H2 2016 1081 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..12), H2 2016 1082 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..13), H2 2016 1083 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..14), H2 2016 1084 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..15), H2 2016 1085 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..16), H2 2016 1086 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..17), H2 2016 1087 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..18), H2 2016 1088 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..19), H2 2016 1089 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..20), H2 2016 1090 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..21), H2 2016 1091 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..22), H2 2016 1092 Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..23), H2 2016 1093 Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H2 2016 1094 Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..1), H2 2016 1095 Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..2), H2 2016 1096 Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..3), H2 2016 1097 Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..4), H2 2016 1098
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
